<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103544</url>
  </required_header>
  <id_info>
    <org_study_id>JONAS-1</org_study_id>
    <nct_id>NCT01103544</nct_id>
  </id_info>
  <brief_title>JAVLOR® Online Non-Interventional Trial</brief_title>
  <acronym>JONAS-1</acronym>
  <official_title>Usage of Vinflunine i.v. (JAVLOR®) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DocCheck Medical Services GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Documentation of data concerning tolerability and efficacy of the intravenous treatment with
      vinflunine performed under daily routine conditions in Germany. The trial focusses on
      tolerability including the assessment of the usage of anti-emetic and anti-obstipative
      concomitant treatment as well as on the efficacy of the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Side effects according to NCI-CTCAE v3.0 and treatment conditions in daily routine</measure>
    <time_frame>9 months after LPI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explorative assessment of Overall Response Rate (ORR)</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetic comedication</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-obstipative diet / comedication</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well-being / quality of life of the patients (patient questionnaire)</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with the treatment (patient questionnaire)</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians' satisfaction with the treatment</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' compliance with regards to the cotreatments (patient questionnaire)</measure>
    <time_frame>9 months after LPI</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transitional Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with advanced / metastatic TCCU after CDDP-failure</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced or metastatic transitional cell carcinoma of the urothelium after
        failure of a Cisplatinum-containing therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Legally competent male and female patients

          -  Advanced or metastatic transitional cell carcinoma of the urothelium

          -  Failure of a prior Cisplatinum-containing treatment

          -  Performance Status 0 or 1

          -  Signed patient informed consent

        Exclusion Criteria:

          -  Missing signed patient informed consent

          -  Performance Status 2 or higher

          -  Life expectancy &lt; 2 months

          -  Brain metastases

          -  Creatinine-clearance &lt; 20 ml/min

          -  Child-Pugh-stadium C

          -  Prothrombin time &lt; 50%

          -  Bilirubin &gt; 5 x ULN

          -  Transaminases &gt; 6 x ULN

          -  Gamma-Glutamyl-transferase &gt; 15 x ULN

          -  Pregnant or breast-feeding women

          -  Known/suspected hypersensitivity against vinflunine or other vinca-alkaloids

          -  Recent (within the last 2 weeks) or current severe infections

          -  Baseline ANC &lt; 1,500/mm3 or platelets &lt; 100,000/mm3

          -  Patients being institutionalised due to court/regulatory order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pierre Fabre Pharma GmbH</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TCCU</keyword>
  <keyword>advanced TCCU</keyword>
  <keyword>metastatic TCCU</keyword>
  <keyword>transitional cell carcinoma of the urothelium</keyword>
  <keyword>advanced transitional cell carcinoma of the urothelium</keyword>
  <keyword>metastatic transitional cell carcinoma of the urothelium</keyword>
  <keyword>Cisplatinum failure</keyword>
  <keyword>Vinflunine</keyword>
  <keyword>Javlor</keyword>
  <keyword>daily routine</keyword>
  <keyword>concomitant antiemetic treatment</keyword>
  <keyword>concomitant antiobstipative treatment</keyword>
  <keyword>concomitant antiobstipative diet</keyword>
  <keyword>patient compliance</keyword>
  <keyword>quality of life</keyword>
  <keyword>non-interventional study</keyword>
  <keyword>Germany</keyword>
  <keyword>Advanced / metastatic TCCU after Cisplatinum-failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

